SCHEMBL8060052

SCHEMBL8060052

CC(C(CCC(=O)O)C(=O)O)P(=O)(O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 6/20 0.53
NAALAD2 Q9Y3Q0 1/20 0.50
CYP1A2 P05177 1/20 0.48
GGH Q92820 1/20 0.46
GRM3 Q14832 2/20 0.46
GABRP O00591 2/20 0.43
GABRD O14764 2/20 0.43
GABRA1 P14867 2/20 0.43
GABRB1 P18505 2/20 0.43
GABRG2 P18507 2/20 0.43
GABRB3 P28472 2/20 0.43
GABRA5 P31644 2/20 0.43
GABRA3 P34903 2/20 0.43
GABRA2 P47869 2/20 0.43
GABRB2 P47870 2/20 0.43
GABRA4 P48169 2/20 0.43
GABRE P78334 2/20 0.43
GABRA6 Q16445 2/20 0.43
GABRG1 Q8N1C3 2/20 0.43
GABRG3 Q99928 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5053274 0.86 GGH (0.49) FOLH1NAALAD2CYP1A2GGHGRM3
SCHEMBL7608707 0.83 FOLH1 (0.44) FOLH1NAALAD2CYP1A2GGHGRM3
SCHEMBL7605307 0.82 GABRP (0.47) FOLH1NAALAD2CYP1A2GGHGRM3
SCHEMBL8048482 0.80 FOLH1 (0.42) FOLH1NAALAD2CYP1A2GGHGRM3
SCHEMBL8469639 0.80 CYP1A2 (0.50) FOLH1NAALAD2CYP1A2GGHGRM3
SCHEMBL9296105 0.79 TDP1 (0.54) FOLH1NAALAD2
SCHEMBL7609969 0.78 FOLH1 (0.40) FOLH1NAALAD2CYP1A2GGHGRM3
SCHEMBL22985 0.78 FOLH1 (0.55) FOLH1NAALAD2CYP1A2GGHGRM3
SCHEMBL8063538 0.77 FOLH1 (0.39) FOLH1NAALAD2CYP1A2GGHGRM3
SCHEMBL7607505 0.77 GGH (0.51) FOLH1CYP1A2GGH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1005348-A1 NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS GUILFORD PHARMACEUTICALS INC. (US) 2000-06-07 EP disclosed
WO-1998013046-A1 NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS GUILFORD PHARMACEUTICALS INC. (US) 1998-04-02 WO disclosed